Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)

Inclusion Criteria: * Healthy male or female subjects between ages of 18-65 years * Body mass index of 18.0-35.0 kg/m2 * Non-smokers for at least 3 months * Deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine * Agree to follow the contraception requirements of the trial * Able to give fully informed written consent. Exclusion Criteria: * Positive tests for hepatitis B \& C, HIV * Severe adverse reaction to any drug * Drug or alcohol abuse * Use of over-the-counter medication (with the exception of paracetamol \[acetaminophen\]) during the 7 days before the first dose of trial medication, or prescribed medication during the 28 days before first dose of trial medication * Any vaccination within 4 weeks before dose of trial medication * Participation in other clinical trials of unlicensed medicines within the previous 3 months * Loss of more than 400 mL blood within the previous 3 months * Vital signs outside the acceptable range * Clinically relevant abnormal findings at the screening assessment * Acute or chronic illness * Clinically relevant abnormal medical history or concurrent medical condition * Possibility that volunteer will not cooperate * Females who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception.